Meta-analysis

Cardiac resynchronization therapy in patients with mild heart failure is a reversal therapy

Sadegh Ali-Hassan-Sayegh a,1,*, Seyed Jalil Mirhosseini a,1, Ali Akbar Karimi-Bondarabadi a, Azadeh Sahidzadeh a, Parisa Mahdavi a, Mahbube Tahernejad a, Safieyehsadat Heydari b, Alexander Weymann c, Mohamed Zeriouh c, Anton Sabashnikov c, Aron-Frederik Popov c

a Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
b Department of Research and Technology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
c Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom

ARTICLE INFO

Article history:
Received 1 July 2015
Accepted 8 August 2016
Available online 25 August 2016

Keywords:
Cardiac resynchronization therapy
Heart failure
Mildly symptomatic

ABSTRACT

This systematic review with meta-analysis sought to determine the efficacy, safety of implantation of cardiac resynchronization therapy (CRT) in mild heart failure (HF). Medline, Embase, Elsevier, and Sciences online database as well as Google scholar literature were used for selecting appropriate studies with randomized controlled design. The literature search of all major databases retrieved 2035 studies. After screening, a total of 10 trials were identified that reported outcomes of interest. Pooled analysis was performed on left ventricular (LV) ejection fraction (P < 0.001), LV end-diastolic volume (P < 0.001), LV end-systolic volume (P < 0.001), LV end-diastolic diameter (P < 0.001), LV end-systolic diameter (P < 0.001), incidence of progression of heart failure (P < 0.001), mortality (P = 0.06), infection (P = 0.1), and pneumothorax (P = 0.08). Overall, implantation of CRT in patients with asymptomatic and mild HF resulted in improved cardiac function, decreased progression of HF, trend to decrease of mortality in short to long-term follow-up.

© 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Heart failure (HF) is considered as an epidemic disease of the modern era nowadays.1–3 Despite recent developments in HF management, the morbidity and mortality in this clinical syndrome remain unacceptably high and patients suffer from debilitating symptoms adversely affecting their quality of life.1–3 Failure may be compounded in patients with intra-ventricular conduction delay possibly due to a loss of ventricular synchroni-

zation.4 Considering the importance of adverse events in this clinical syndrome, there is an emerging emphasis on understand-
ing the progression from heart failure risk factors to asymptomatic ventricular dysfunction and eventually to symptomatic heart failure and death.1,4 The placement of an implantable cardiover-
ter-defibrillator (ICD) improves survival and reduces the risk of sudden death. However, life-prolonging defibrillator therapy is

associated with an increased risk of first and recurrent HF events.5 Cardiac resynchronization therapy (CRT) can improve symptoms of HF, quality of life, exercise capacity, and left ventricle function when used in patients suffered from symptomatic HF with New York Heart Association (NYHA) functional class III or ambulatory class IV with a wide QRS complex.6,7 Recently, the ACCF/AHA guidelines limited the Class I indication for CRT to patients with a QRS duration ≥ 150 ms.6,7 However, a QRS duration of 120–150 ms is still recommended as the Class I indication in the European Society of Cardiology (ESC) guidelines if the patient has an LBBB pattern and depressed LVEF.8,9 Also, according to Tracey et al., CRT can be useful (Class IIa indication) for patients who have LVEF less than or equal to 35%, sinus rhythm, a non-LBBB pattern with a QRS duration greater than or equal to 150 ms, and NYHA class III/ambulatory class IV symptoms on GDHT.8 Since progression of clinical symptoms from mild to severe HF may result from insufficient and inappropriate treatments, current management focuses on introducing treatments with ability of reversing HF symptoms. Several studies have reported the efficacy and safety of implantation of CRT in asymptomatic or mild HF. However, data from RCTs are limited and so far largely inconclusive. This systematic review with meta-analysis sought to determine the
strength of evidence for the effects of CRT on changes in left ventricular ejection fraction (LVEF), left ventricular end diastolic (LVEDV) and end systolic volumes (LVESV), left ventricular end diastolic (LVEDD) and end systolic diameters (LVESD), left ventricular end systolic volume index (LVESVI), and impact on incidence of HF, mortality, infection, pneumothorax, and hematoma required intervention.

2. Methods and materials

2.1. Literature search

A comprehensive literature search was conducted in major electronic databases (Medline/Pubmed, Embase, Elsevier, Web of Knowledge, Sciences online database and Google Scholar) from their inception through July 25, 2014 to identify the RCTs reporting the effects of CRT on echocardiographic results and clinical outcomes in patients with mild HF. Predefined search terms included: “cardiac resynchronization therapy”, “CRT”, “biventricular pacing”, “biventricular pacemaker”, and “heart failure”, “HF”, “mild HF”. No language restrictions were applied. All retrieved references of the included RCTs were also reviewed to determine additional studies not indexed in the common databases. Studies were included into the analysis when they met the following criteria: (1) RCT, (2) comparison of CRT with a control group, and (3) reporting data on the echocardiographic results and clinical outcomes according to our review-checklist. In addition, abstracts without peer-review publications of manuscripts were not included.

2.2. Data extraction and outcome measures

Two investigators (S.A.-H.-S. and A.A.K.-B.) extracted the data independently, and discrepancies were resolved via a consensus standardized abstraction checklist used for recording data in each study. Data retrieved from the trials included: author’s name, mean age, gender, sample size, study design, type of controls, duration of follow-up, primary and secondary endpoints, NYHA class, consumption of beta blocker, diuretics, angiotensin converting enzyme inhibitors and angiotensin receptor blockers, Jadad score. For each group the following data were recorded: LVEF, LVESV, LVEDV, LVESD, LVESVI, incidence of heart failure, mortality, infection, pneumothorax, and hematoma required intervention. For exploration of heterogeneity among trials, a subgroup analysis of disparities in the patients’ characteristics was performed for (1) average age (<65 years vs. ≥65 years), (2) percentage of male gender (<80% vs. ≥80%), (3) follow-up duration (<6 months vs. ≥6 months), (4) sample size (<500 vs. ≥500).

2.3. Statistical analysis, publication bias and quality assessment

Data were analyzed by STATA version 11.0 utilizing METAN and METABIAS modules. The effect sizes measured were odds ratio (OR) with 95% confidence interval (CI) for categorical variables. Regarding non-categorical data, weighted mean difference (WMD) with 95% CI was used for calculating differences between intervention and control groups. OR <1 favored CRT and OR >1 favored control. RCTs with no events in the 2 arms were discarded from pooled analysis. Forest plots were created for each outcome. A value of P < 0.1 for Q test or I² > 50% indicated significant heterogeneity among the studies. Non-significant heterogeneity among studies was accounted for by applying a random effect model when indicated. The presence of publication bias was evaluated using the Begg and Egger tests. Quality assessment of RCTs was performed using the Jadad score. The Jadad score assesses 3 items including randomization (0–2 points), blinding of study (0–2 points) and withdrawals and dropouts (0–1 points). Higher scores indicate better reporting (“high” quality: 5; “good” quality: 3–4; “poor” quality: 0–2). Results were considered statistically significant at a P-value < 0.05.

3. Results

3.1. Literature search strategy and included trials

Literature search retrieved 2035 studies from screened databases of which 1769 (86.9%) were excluded after initial review. Of 266 primarily included studies, 256 were excluded after detailed evaluation due to insufficient reporting of endpoints of interest. The final analysis included 10 RCTs.

3.2. Study characteristics, effect measures and clinical outcomes

3.2.1. Left ventricular ejection fraction

A total of 2582 patients were included from 5 RCTs reporting data on LVEF. Patient population of RCTs ranged from 36 to 1820 patients (Table 1). From all patients, 1463 were allocated to CRT and 1119 to the control group. Mean increase in LVEF for all trials was 5.1 ± 5.6 with 6.78 ± 6.14 for CRT and 3.42 ± 5.24 for the control group (Table 2). Applying a random effect model, pooled analysis revealed that CRT succeeded in increasing ejection fraction mildly with a WMD of 2.88 (95% CI: 2.77–3; P < 0.001) (Fig. 1). There was a significant heterogeneity among the studies (chi-squared = 857.25, I² = 99.5%, P < 0.001). The subgroup analysis is presented in Table 3.

3.2.2. Left ventricular end diastolic and end systolic volume

A total of 2042 cases were included from 3 RCTs reporting data on LVEDV and LVESV. Patient population of RCTs ranged from 36 to 1820. From all patients, 1193 were allocated to CRT and 849 to the control group (Table 1). Mean decrease in LVEDV for all trials was −29.31 ± 52.2 with −44.6 ± 59.9 for CRT and −14.5 ± 44.5 for the control group, and mean decrease in LVESV for all RCTs was −32.1 ± 49.6 with −46.7 ± 56.4 for CRT and −15.7 ± 42.8 for the control group, respectively (Table 2). Applying a random effect model, pooled analysis reported that CRT therapy could significantly decrease LVEDV (WMD of −37.31; 95% CI: −39.53 to −35.1; P < 0.001) and LVESV (WMD of −39.02; 95% CI: −41.2 to −36.84; P < 0.001). There was no significant heterogeneity among the studies for LVEDV and LVESV analyses (I² = 0.0% for both).

3.2.3. Left ventricular end diastolic diameter and end systolic diameter

A total of 2346 cases were included from 3 RCTs reporting data on LVEDD and LVESD. Patient population of RCTs ranged from 36 to 1820. From all patients, 1353 were allocated to CRT and 993 to the control group (Table 1). Mean decrease in LVEDD for all trials was −2.4 ± 3.4 with −4.1 ± 3.7 for CRT and −0.8 ± 3.1 for the control group, and mean decrease in LVESD for all RCTs was −3.6 ± 4 with −5.7 ± 4.4 for CRT and −1.6 ± 3.6 for the control group, respectively (Table 2). Applying a random effect model, pooled analysis reported that CRT could significantly decrease LVEDD (WMD of −3.96; 95% CI: −3.75 to −3.15; P < 0.001) and LVESD (WMD of −3.96; 95% CI: −3.75 to −3.15; P < 0.001). There was a significant heterogeneity among the studies for LVEDD and LVESD (I² = 99.1% for LVEDD and I² = 99.6% for LVESD).

3.2.4. Left ventricular end systolic volume index

A total of 2082 patients were included from 2 RCTs reporting data on LVEF; 1269 were allocated to CRT and 813 to the control group. Applying a random effect model, pooled analysis revealed that CRT succeeded in significantly decreasing LVESVI index with a
### Table 1
Demographic data of included studies.

| Author (references) | N    | Mean age (yrs) | Male (%) | Mean LVEF (%) | Mean LVEDV (ml) | Mean LVESV (ml) | ORS (ms) |
|---------------------|------|----------------|----------|---------------|----------------|----------------|----------|
|                     | CRT  | C              | CRT      | C             | CRT            | C              | CRT      |
| MADIT CRT10         | 1089 | 791            | 65       | 64            | 74.7           | 75.6           | 24       |
| Greater-earth trial11 | 61   | 60             | 61       | 61            | 75             | 75             | 24       |
| Gierula12           | 25   | 25             | 77       | 77            | 64             | 64             | 39       |
| REVERSE trial13     | 180  | 82             | 61.7     | 60.4          | 79             | 85             | 28.1     |
| CONTACT trial14     | 245  | 245            | 66       | 66            | 85             | 85             | 21       |
| Van Geldorp15       | 19   | 17             | 64       | 67            | 78.9           | 76.4           | 36       |
| RAFT trial16        | 894  | 904            | 66.1     | 66.2          | 84.8           | 81             | 22.6     |
| Narrow-CRT trial17  | 60   | 60             | 65       | 68            | 88             | 83             | 28       |
| MIRACLE trial18     | 85   | 101            | 63.1     | 63.1          | 82.2           | 90.1           | 24.4     |
| CARE-HF trial19     | 86   | 89             | 64       | 64            | 77             | 77             | 24.8     |

### Table 2
Clinical outcomes of included studies.

| Author (references) | LVEF (%) | LVEDV | LVESV | LVEDD | LVESD |
|---------------------|----------|-------|-------|-------|-------|
|                     | CRT      | C     | CRT   | C     | CRT   | C     |
| MADIT CRT10         | 11 ± 5    | 3 ± 3 | 52.2 ± 33.2 | −14.7 ± 14.4 | −57.3 ± 31.2 | −18.1 ± 16.3 | −6 ± 3.4 | −1.5 ± 1.5 | −8.9 ± 4.4 | −2.5 ± 2.2 |
| Greater-earth11     | N.D.      | N.D.  | N.D.  | N.D.  | N.D.  | N.D.  | N.D.  | N.D.  | N.D.  | N.D.  |
| Gierula12           | 9 ± 6     | −1.5 ± 5.3 | N.D.    | N.D.    | N.D.    | N.D.    | N.D.    | N.D.    | N.D.    | N.D.    |
| REVERSE trial13     | 5.1 ± 0.7 | 2.8 ± 0.7 | N.D.    | N.D.    | N.D.    | N.D.    | N.D.    | N.D.    | N.D.    | N.D.    |
| CONTACT trial14     | 5 ± 11    | 12 ± 11 | −39 ± 70.5 | −13 ± 57.3 | −41 ± 61 | −15 ± 55.3 | −4 ± 7   | −1 ± 7   | −5 ± 8   | −2 ± 8   |
| Van Geldorp15       | 3.8 ± 8   | 0.8 ± 6.2 | −41 ± 76 | −16 ± 62 | −42 ± 77 | −14 ± 57 | N.D.    | N.D.    | N.D.    | N.D.    |
| RAFT trial16        | 3.8 ± 8   | 0.8 ± 6.2 | −41 ± 76 | −16 ± 62 | −42 ± 77 | −14 ± 57 | N.D.    | N.D.    | N.D.    | N.D.    |
| Narrow-CRT trial17  | 3.8 ± 8   | 0.8 ± 6.2 | −41 ± 76 | −16 ± 62 | −42 ± 77 | −14 ± 57 | N.D.    | N.D.    | N.D.    | N.D.    |
| MIRACLE trial18     | 3.8 ± 8   | 0.8 ± 6.2 | −41 ± 76 | −16 ± 62 | −42 ± 77 | −14 ± 57 | N.D.    | N.D.    | N.D.    | N.D.    |
| CARE-HF trial19     | 3.8 ± 8   | 0.8 ± 6.2 | −41 ± 76 | −16 ± 62 | −42 ± 77 | −14 ± 57 | N.D.    | N.D.    | N.D.    | N.D.    |

### Author (references)

| LVEF (%) | CRT    | C     | LVEDV | CRT    | C     | LVESV | CRT    | C     | LVEDD | CRT    | C     | LVESD | CRT    | C     |
|----------|--------|-------|-------|--------|-------|-------|--------|-------|-------|--------|-------|-------|--------|-------|
|          | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     |
| MADIT CRT10 | −28.7 ± 15.5 | −9.1 ± 8.2 | 136 | 140 | 36 | 18 | 12 | 5 | 19 | 6 | 36 | 18 |
| Greater-earth11 | N.D. | N.D. | 8 | 4 | 2 | 2 | N.D. | N.D. | N.D. | 2 | 1 | N.D. | N.D. | N.D. | N.D. |
| Gierula12 | −27.5 ± 31.8 | −2.7 ± 25.8 | 13 | 14 | 10 | 7 | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. |
| REVERSE trial13 | N.D. | N.D. | 32 | 39 | 11 | 16 | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. |
| CONTACT trial14 | N.D. | N.D. | 0 | 0 | 0 | 0 | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. |
| Van Geldorp15 | N.D. | N.D. | 174 | 236 | 130 | 162 | 21 | 16 | 11 | 8 | 14 | 11 |
| RAFT trial16 | N.D. | N.D. | 5 | 11 | 4 | 5 | 2 | 1 | N.D. | 1 | 1 |
| Narrow-CRT trial17 | N.D. | N.D. | 7 | 19 | 2 | 2 | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. |
| MIRACLE trial18 | N.D. | N.D. | 23 | 27 | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. |

### Author (references)

| LVEF (%) | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     |
|----------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|
|          | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     | CRT    | C     |
| MADIT CRT10 | 7 years | ICD + CRT vs. ICD | This study indicated that in patients with mild heart-failure symptoms, left ventricular dysfunction, and left bundle-branch block, early intervention with CRT-D was associated with a significant long-term survival benefit |
| Greater-earth11 | 5 years | ICD + CRT (on) vs. ICD + CRT (off) | This study indicated that in patients with mild HF, CRT produced reverse LV remodeling accompanied by very low mortality and need for heart failure hospitalization. These effects were sustained over 5 years. Cardiac resynchronization therapy in addition to optimal medical therapy produces long-standing clinical benefits in mild heart failure |
WMD of $-19.71$ (95% CI: $-20.79$ to $-18.63$; $P < 0.001$). There was no significant heterogeneity among the studies (chi-squared = 1.92, $I^2 = 48$%, $P = 0.1$).

### 3.2.5. Incidence of progression of heart failure

A total of 4847 patients were included from 8 RCTs reporting data on the incidence of progression of HF. Patient population of RCTs ranged from 50 to 1820 subjects (Table 1). From all cases, 2639 were allocated to CRT and 2208 to the control group (Tables 1–2). The overall incidence of heart failure was 17.33% ranging from 4% to 22.8%. Progression of heart failure occurred in 14.2% in CRT group and 21.05% in control group (Table 2). Pooled treatment effect analysis revealed that CRT could significantly decrease the incidence of progression of heart failure with an OR of 0.64 (95% CI: 0.55–0.74; $P < 0.001$) using a fixed model (Fig. 2). No significant heterogeneity was observed among the RCTs (Chi-squared = 8.76, $I^2 = 20.1$%, $P = 0.2$). Begg and Egger tests showed no potential publication bias among the included RCTs (Begg test, $P = 1.0$; Egger test, $P = 1.0$).

### 3.2.6. Mortality

Ten RCTs (5058 patients) reported data on death. Mortality occurred in 7.98% in CRT group and 10.41% in control group (Table 2). In fact 1 out of 10 comparisons did not present any postoperative death events in 2 comparative arms, therefore, the

---

**Table 3**

Subgroup analysis for clinical outcomes.

| Subgroup                             | Studies (N) | Odd ratio or SMD (95% CI) | $P$-value |
|--------------------------------------|-------------|---------------------------|-----------|
| S.G.A for left ventricle ejection fraction (LVEF) according to SMD |
| Age (years)                          |             |                           |           |
| ≤65                                  | 2           | 1.67 (1.57 to 1.77)       | <0.001    |
| >65                                  | 3           | 2.62 (2.38 to 2.86)       | <0.001    |
| Male (%)                             |             |                           |           |
| ≤80                                  | 4           | 1.99 (1.89 to 2.09)       | <0.001    |
| >80                                  | 1           | 0.42 (0.13 to 0.71)       | 0.004     |
| Follow up                            |             |                           |           |
| ≤6 months                            | 4           | 1.75 (1.57 to 1.93)       | <0.001    |
| >6 months                            | 1           | 1.85 (1.74 to 1.96)       | <0.001    |
| Sample size                          |             |                           |           |
| ≤500                                 | 4           | 1.75 (1.57 to 1.93)       | <0.001    |
| >500                                 | 1           | 1.85 (1.74 to 1.96)       | <0.001    |
| S.G.A for left ventricle end diastolic and systolic diameter (LVEDD and LVESD) according to SMD |
| Age (years)                          |             |                           |           |
| ≤65                                  | 1           | -1.60 (−1.71 to −1.50)    | <0.001    |
| >65                                  | 2           | -0.26 (−2.90 to −2.41)    | <0.001    |
| Male (%)                             |             |                           |           |
| ≤80                                  |             |                           |           |
| All studies have male percentage less than 80% |
| >80                                  |             |                           |           |
| Follow up                            |             |                           |           |
| ≤6 months                            | 2           | -2.66 (−2.90 to −2.41)    | <0.001    |
| >6 months                            | 1           | -1.60 (−1.71 to −1.50)    | <0.001    |
| Sample size                          |             |                           |           |
| ≤500                                 | 2           | -2.66 (−2.90 to −2.41)    | <0.001    |
| >500                                 | 1           | -1.60 (−1.71 to −1.50)    | <0.001    |

---

**Fig. 1.** Forest plot of weighted mean differences (WMD) for treatment with cardiac resynchronization therapy on left ventricle ejection fraction.

**Fig. 2.** Forest plot of odds ratio (OR) for treatment with cardiac resynchronization therapy on progression of heart failure.
remaining 9 RCTs (5022 cases) were used to perform the meta-analysis. Pooled treatment effect analysis revealed that CRT had a statistical trend toward reduction in mortality with an OR of 0.83 (95% CI: 0.68–1.01; P = 0.06) using a fixed model (Fig. 3). No significant heterogeneity was observed among the RCTs (chi-squared = 3.95, P = 0.08). Begg and Egger tests showed no potential publication bias among the included RCTs (Begg test, P = 0.655; Egger test, P = 0.655).

3.2.7. Infection

Three RCTs (3738 cases) reported data on the occurrence of infection. Overall incidence of infection was 1.54%: 1.71% in CRT group and 1.29% in control group (Tables 1–2). Pooled analysis indicated that CRT group had trend toward increased incidence of infections with an OR of 1.44 (95% CI: 0.83–2.09; P = 0.06) using a fixed model. No significant heterogeneity was observed among the included RCTs (Begg test, P = 0.117; Egger test, P = 0.117).

3.2.8. Pneumothorax

Two RCTs (3618 cases) reported data on the occurrence of pneumothorax. Overall incidence of pneumothorax was 1.21%; 1.51% in CRT group and 0.85% in control group. Pooled analysis revealed that CRT group had trend toward increased incidence of pneumothorax with an OR of 1.75 (95% CI: 0.91–3.33; P = 0.08) using a fixed model. No significant heterogeneity was observed among the RCTs (chi-squared = 0.42, I² = 0.0%, P = 0.5).

3.2.9. Hematoma required intervention

A total of 3738 patients were included from 3 RCTs reporting data on the incidence of hematoma. From these cases, 2043 were allocated to CRT and 1695 to the control group. The overall incidence of hematoma was 2.16% ranging from 1.3% to 2.9%. Hematoma occurred in 2.49% in CRT group and 1.76% in control group. Pooled analysis indicated that CRT did not significantly increase the incidence of hematoma with an OR of 1.32 (95% CI: 0.83–2.09; P = 0.2) using a fixed model. No significant heterogeneity was observed among the RCTs (chi-squared = 0.05, I² = 0.0%, P = 0.9).

4. Discussion

Early diagnosis and appropriate treatment are of critical importance in HF: if the disease is controlled at earlier stages, survival and quality of life in patients are more likely to improve.1 3 According to guidelines, CRT when used in patients with moderate and severe HF, will be able to significantly improve clinical symptoms, quality of life, return to work, physical activities, and left ventricular function.2–4 Therefore, beneficial effects of CRT implantation in patients with NYHA class III and IV resulted in effective and efficient treatment before the patient required heart transplant.2–4 It is obvious that in HF, decreased left ventricular function results in increasing residual blood volume at the end of systole and diastole with consequently increasing left ventricular diameters and decreasing LVEF. Therefore, the more this vicious cycle continues, the higher the failure grade and more the clinical symptoms appear.

The main findings of our study are that CRT could significantly reduce residual blood volume and diameters of the left ventricle at the end of systole and diastole, and also increase LVEF. Given the fact that the follow-up period might be an important factor to detect an improvement in patients with mild HF, another noted difference is that we used extended follow-up of the REVERSE Trial: 24 months clinical and left ventricle remodeling which were reported by the European cohort.13 REVERSE Trial suggested that clinical outcomes and LV function were improved and LV dimensions were decreased in a patient population in NYHA class I or II.13

Our findings revealed that CRT could considerably prevent progression of HF, therefore, in patients with mild HF, CRT implantation at earlier stages of HF could be used in order to prevent worsening of clinical signs and decrease the cases of severe HF requiring heart transplant, thus being considered as reversal therapy. Lubitz et al. reported that CRT in patients with mild HF symptoms, left ventricular dysfunction, sinus rhythm and prolonged QRS duration could decrease HF events.26 In the current study, CRT was also shown to have a strong tendency toward decreasing mortality (although not statistically significant). A study by Tu et al. also stated that CRT could significantly decrease all-cause mortality which confirms our deduction.27 MADIT-CRT showed that CRT combined with ICD decreased the risk of heart failure events in relatively asymptomatic patients with LVEF less than 30% and wide QRS complex. The absence of an observed mortality benefit in this trial was probably due to a very low annual mortality rate (3%) throughout the course of the study period.10

A foreign material in the body may develop complications including hemorrhage related to implant placement, such as hematoma requiring intervention and infection.25–27 The results of
our study revealed that the patients with CRT were more prone to develop infection and pneumothorax, however the incidence of hematoma requiring intervention was comparable to the control group. The importance of this issue lies in the fact that for using beneficial effects of CRT, other treatments managing CRT complications should be considered for the patients, such as appropriate prophylactic antibiotics along with CRT implant placement in order to decrease the risk of infection, accurate radiographic and clinical investigations looking for pneumothorax, and opportune intervention when such complications appear. Previous studies have revealed that CRT could significantly increase the incidence of LV lead repositioning, infection, pneumothorax, hematoma, and coronary venous dissection. Although many of these adverse events did not have substantial long-term consequences, they may cause substantial morbidity and increase the overall costs to health care system.\textsuperscript{28–30} Burri et al. argued that although CRT improved patients’ outcome, this was at the expense of a greater rate of device-related complications such as infections and stimulation of phrenic nerve and lead repositioning compared with ICD implantation.\textsuperscript{31} RAFT reported that patients with NYHA class II or III heart failure, a wide QRS complex, and left ventricular systolic dysfunction, the addition of CRT to an ICD reduced rates of death and hospitalization for heart failure. This improvement was accompanied by more adverse events such as left ventricular lead dislodgement and infection.\textsuperscript{16} MADIT-CRT showed that CRT was associated with a significant decrease of mortality and HF events during 7 years follow-up in patients with mild HF symptoms, left ventricular dysfunction and left bundle-branch block.\textsuperscript{20} Also the results of a 5-year-follow-up (REVERSE study) indicated that in patients with mild HF, CRT produced reverse LV remodeling, accompanied by very low mortality and need for HF hospitalization. CRT in addition to optimal medical therapy produced long-term clinical benefits in mild HF.\textsuperscript{21} On the other hand, several studies examined medical costs in patients with mild HF, strongly emphasizing that CRT reduced total medical costs in patients with asymptomatic and mild HF compared to optimal medical therapy.\textsuperscript{22–24}

5. Limitation

Our study is associated with several limitations. Data from some end-points of interest were not available for all studies, and we did not contact the authors to obtain unpublished data. Additionally, the absence of patient-level data limits our ability to assess sensitive patient-based subgroup analysis about effects of CRT on clinical or functional outcomes.

6. Conclusion

Implantation of CRT in patients with asymptomatic and mild HF can result in improved cardiac function, decreased progression of HF from mild to severe, reduced mortality in short to long-term follow-up. Although risk of complications such as infection, and pneumothorax increased after implantation of CRT, it is recommended to recognize the complications at earlier stages and use supplementary treatments and appropriate controls. As CRT also reduces medical costs in patients with mild HF compared with optimal medical therapy we strongly recommend this treatment strategy for patients with mild HF as an economical treatment with high efficiency.

Conflicts of interest

The authors have none to declare.

Acknowledgments

We would like to thank for their assistance Dr. Fatemeh Haddad, and Dr. Arezoo Shahidzadeh to writing of manuscript, and Dr. Elham Rahimizadeh, Dr. Zahra Sarrafan, Dr. Zahra Chodratpour, and Dr. Ali Mohammad Dehghan for their assistance to collecting data and statistical analysis. The authors are indebted to Al-Majed et al. for their interesting article entitled “Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure."\textsuperscript{32}

References

1. Nannad F, Agrinier N, Alla F. Heart failure burden and therapy. Europe. 2009;11(Suppl. 5):v1–v9.
2. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1–e90.
3. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association for the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–2442.
4. Bakker PF, Meijburg HW, de Vries JW, et al. Biventricular pacing in end-stage heart failure improves functional capacity and left ventricular function. J Interv Card Electrophysiol. 2000;4:395–404.
5. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
6. Jeevanantham V, Daubert JP, Zareba W. Cardiac resynchronization therapy in heart failure patients: an update. Cardiol J. 2009;16:164–170.
7. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.
8. Tzekov, CM, Epstein AE, Darbar D, et al. ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [corrected]. Circulation. 2012;126:1784–1800.
9. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–1852.
10. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–1338.
11. Thabah B, Harel F, Ducharme A, et al. Evaluation of resynchronization therapy for heart failure in patients with a QRS duration greater than 120 ms (GREATER-EARTH): trial: rationale, design, and baseline characteristics. Can J Cardiol. 2011;27:779–786.
12. Gersula J, Cubbon RM, Jamil HA, et al. Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction. Europace. 2013;15:1609–1614.
13. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009;54:1837–1846.
14. Hoggins SL, Hummel JD, Nizzi I, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454–1459.
15. vander Gelper IE, Vernooij D, Delhaas T, et al. Beneficial effects of biventricular pacing in chronically right ventricular paced patients with mild cardiomyopathy. Euro- pace. 2010;12:223–229.
16. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–2395.
17. Mueller C, Selimene F, Galloway T, et al. A randomized study of cardiac resynchronization therapy defibrillator versus dual-chamber implantable cardioverter-defibrillator in ischemic cardiomyopathy with narrow QRS: the NARROW-CRT study. Circ ArrhythmElectrophysiol. 2015;8:538–545.
18. Abraham WT, Young JB, León AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864–2868.
19. Cleland JG, Freemantle N, Daubert JC, Toff WD, Leisch F, Tavazzi L. Long-term effect of cardiac resynchronization in patients Reporting mild symptoms of heart failure: a report from the CARE-HF study. Heart. 2008;94:278–283.
20. Goldenberg I, Konyilá V, Klein HJ, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370:1694–1701.
21. Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the Resynchronization reVerSes Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34:2592–2599.

22. Linde C, Mealing S, Hawkins N, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J. 2011;32:1631–1639.

23. Almenar L, Díaz B, Quesada A, et al. Cost-effectiveness analysis of cardiac resynchronization therapy in patients with NYHA I and NYHA II heart failure in Spain. Int J Technol Assess Health Care. 2013;29:140–146.

24. Poggio R, Augustovsky F, Caporale J, Irazola V, Miriuca S. Cost-effectiveness of cardiac resynchronization therapy: perspective from Argentina. Int J Technol Assess Health Care. 2012;28:429–435.

25. Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force. American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;63:380–406.

26. Lubitz SA, Leong-Sit P, Fine N, Kramer DB, Singh J, Ellinor PT. Effectiveness of cardiac resynchronization therapy in mild congestive heart failure: systematic review and meta-analysis of randomized trials. Eur J Heart Fail. 2010;12:360–366.

27. Tu R, Zhong G, Zeng Z, et al. Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther. 2011;25:331–346.

28. Romeyer-Bouchard C, Da Costa A, Dauphinot V, et al. Prevalence and risk factors related to infections of cardiac resynchronization therapy devices. Eur Heart J. 2010;31:203–210.

29. León AR, Abraham WT, Curtis AB, et al. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. J Am Coll Cardiol. 2005;46:2348–2356.

30. Duray GZ, Schmitt J, Czek-Hartvig S, Hohnloser SH, Israel CW. Complications leading to surgical revision in implantable cardioverter defibrillator patients: comparison of patients with singlechamber, dualchamber, and biventricular devices. Europace. 2009;11:297–302.

31. Burri H. Cardiac resynchronization therapy for mild-to-moderate heart failure. Expert Rev Mol Diagn. 2011;8:313–317.

32. Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med. 2011;154:401–412.